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Abstract 
Acne causes profound negative psychological and social effects on the quality of life (QoL) of 
patients. The European Dermatology Forum S3-Guideline for the Treatment of Acne 
recommended adopting a QoL measure as an integral part of acne management. Because of 
constantly growing interest in Heath-related QoL assessment in acne and because of the high 
impact of acne on patients’ lives, the European Academy of Dermatology and Venereology Task 
Forces on QoL and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa 
has documented the QoL instruments that have been used in acne patients, with information on 
validation, purposes of their usage, description of common limitations and mistakes in their 
usage and overall recommendations. 
Introduction 
Acne is common dermatologic diagnosis accounting for 22–32% of dermatology patients and is 
one of the most common reasons for visiting a physician (1.1%)1 with an estimated prevalence of 
650 million people affected.2 A systematic analysis for the Global Burden of Disease study 
indicated that acne was the 8th most prevalent disease globally in 2010.3 Acne is considered a 
chronic disease owing to its prolonged course, pattern of recurrence and relapse, and 
manifestations such as acute outbreaks or slow onset. Moreover, the disease causes profound 
negative psychological and social effects on the quality of life (QoL) of patients.4 Most people 
experience acne during adolescence, with >95% of teenage boys and 85% of teenage girls 
affected.5 Of these young people, 20-40% have moderate-to-severe acne and as many as 50% 
continue to suffer from acne in adulthood. Familial predisposition and especially acne in the 
mother are significantly associated with a more severe course.5 Acne patients are managed 
primarily by dermatologists (93%) but also by general practitioners (6.3%) and pediatricians 
(0.6%).6 In 2004, the direct annual costs in the USA had climbed to over 2.2 billion US dollars.7 
Patients with clinical acne require medical therapy, either because of the severity or duration 
of their disease. Recent scientific advances have contributed to a better understanding of the 
pathogenesis of acne and to optimizing the therapeutic approach.8-12 Health-Related QoL 
(HRQoL) assessment in patients with acne are recommended by several national guidelines.13 
The European Dermatology Forum S3-Guideline for the Treatment of Acne recommended 
adopting a QoL measure as an integral part of acne management.14 
HRQoL assessment in acne patients is often used in clinical trials as an outcome measure but 
there are also many reasons to measure HRQoL in clinical practice.15 To facilitate the integration 
of thinking about QoL into routine clinical practice the new word “QUIMP”, meaning quality of 
life impairment, was recently proposed.16 
Because of growing interest in the assessment of HRQoL in acne and the major impact of 
acne on patients’ lives, the European Academy of Dermatology and Venereology (EADV) Task 
Forces (TFs) on QoL and Patient Oriented Outcomes (POO) and Acne, Rosacea and Hidradenitis 
Suppurativa (ARHS) have documented the QoL instruments that have been used in acne 
patients, with information on validation, purposes of their usage, description of common 
limitations and mistakes in their usage and overall recommendations of the TFs. 
 
 
This information should assist dermatologists and researchers in choosing appropriate QoL 
instruments, avoid common mistakes and facilitate the use of validated QoL instruments in their 
research and clinical work. 
 Methods 
Members of the EADV TFs on QoL and POO and ARHS were invited to participate. A literature 
search was performed using the PubMed database, which was searched from 1980 to November 
2016 using the key words combination: “acne” and “quality of life”. All publications written in 
English or that had English abstracts were considered. All those who volunteered were allocated 
a section of the identified articles to review. 
Exclusion criteria: 
- Review articles, guidelines, protocols  
- Studies without HRQoL assessment 
- Measurement of HRQoL in conditions other than acne  
- Studies where HRQoL was measured in patients with conditions other than acne but 
some of whom may also have acne 
- Studies where HRQoL was studied in acne and other diseases but results on acne were 
not presented and/or discussed separately  
- Studies on post-acne scars and post-acne hyperpigmentation 
All publications were independently assessed by two co-authors. The assessments were 
compared and discrepancies discussed and resolved. The remaining publications were analyzed 
in detail and the QoL instruments used in acne were listed. Additional PubMed searches were 
carried out for “acne” and the name of each of the measures from this list.  
Results 
 
13 members of the EADV Task Forces took part in the literature review.  Figure 1 shows the 
literature search procedure. Validated HRQoL instruments that were used in acne studies are 
described in Table 1. Figure 2 shows how frequently these instruments were used. 
Pärna et al38 used the RAND-36 instrument: this has identical content to the SF-36 but 
has a slightly different scoring system. Acne patients were included in the creation and initial 
validation of the 11-item Turkish quality of life (TQL) instrument199. The Children's Life Quality 
Index (CLQI), a 12-item generic proxy instrument has been used to compare children with skin 
disease with children with other chronic diseases176. Two German instruments were also used to 
assess HRQoL in acne patients98,200 . 
Truchuelo et al201 reported the use of the 9-item Social Quality-of-Life (SOQOL) scale, citing 
Krejci-Manwaring et al.89 . However Krejci-Manwaring et al89 do not give information on the 9-
item instrument. Nair and Nair appear to have combined the DLQI and CADI under the title 
Total Acne Quality of Life (TAQOL)202. Five “study-specific” untitled questionnaires with QoL 
elements were also used in acne patients203-207.  
There are several reports of acne studies in which QoL instruments were used outside their 
validated age limits. For example, Skindex-29, an instrument for adults, was used in children 
from 12 years old79 and the DLQI, designed for use in those over 16 years old, was used in 
children aged 15 22,37 , 14 42, 55, 13 48 and 12 years old25.  
The titles of some QoL instruments have been inaccurately presented.45, 159 Some authors 
did not provide references for the QoL instruments that they used79,160. 
Most of the publications identified were clinical trials, epidemiologic studies and studies 
on creation and/or validation of QoL instruments. However, there were also publications on 
educational work in acne patients39,51,181, compliance and adherence to treatment25,83,142, 
correlation of QoL with acne severity measures 26,74, psychological problems23,38,41,45,47,54, 
65,94,99,120,175,190,200
, gender differences28, 102, racial differences140, comparison of generic and 
disease-specific QoL instruments 34,61, and comparison of QoL impairment in patients with acne 
and other diseases 35,47, 60, 78, 85,169, 176.  
Clinical trials 
The different interventions assessed, for which the greatest number of studies have been 
identified, were those concerning isotretinoin 18, 19, 22, 40, 41, 52, 54, 106, 136, 170,171, 185, 188 and benzoyl 
peroxide 76, 77, 79, 117, 133, 135, 152, 157, 162, 179.   
Epidemiologic studies  
A study from France showed that quimp in women with acne, assessed by the DLQI, was 
significantly different from women without acne.62 Another French study reported that patients’ 
daily lives were affected in nearly half of acne patients (48%).103 A study from Iraq found 
significant association between age and QoL impairment in 510 acne patients.111 
Acne influenced QoL “moderately” to “very much”, in 51.8% of patients in a study from Iran.31  
On the other hand, 478 Serbian pupils with self-reported acne reported low HRQoL 
impairment.112   
Educational work in acne patients  
Mean DLQI39,51 and CADI39 scores improved after 12 weeks of text messages39 and multiple-
choice questions.51 Internet-based acne education using automated counseling was not superior 
to standard-website education in improving acne severity and QoL181. 
Compliance and adherence to treatment  
In patients with acne, being female, married, employed and not paying for prescriptions were 
characteristics associated with increased medication adherence and better HRQoL25. Young 
females with high Skindex-29 scale scores and males with low Skindex scores are especially 
prone to non-adherence.83  Better adherence was related to lower Skindex-29 scale scores at the 
end of their study83.  Zaghoul et al. found significant negative correlation between DLQI scores 
and medication adherence25. Tan et al. reported that adherence increases with greater levels of 
impact on acne-specific QoL assessed by the Acne-QoL questionnaire 142 
Correlation of QoL with acne severity measures  
In the majority of studies that addressed the issue,  HRQoL correlated with acne severity. 89, 177, 
187  Hanisah et al. found that only students with severe acne, assessed with the global acne 
grading system (GAGS), had high CADI scores 123. There was a positive correlation between 
overall scores on the Echelle de Cotation des Lésions d'Acné (ECLA) scale and CADI scales 
before and after treatment in one study 115 but no correlation in another study102.  Some studies 
found no correlation between the impairment of QoL and the severity of acne.26,110,118  The report 
of a case-control study in university students stated that even though the AQOL and DLQI scores 
were significantly higher in acne patients compared to controls, the level of impairment of QoL 
was not associated with the severity of acne.26  In addition, there was no correlation between 
CADI scores and GAGS in an acne study of female patients118. 
Psychological problems  
A high impairment of dermatologic QoL seems to be associated with an increased risk of having 
an anxiety disorder65. Anger was significantly related to both global QoL and skin-related QoL 
in the study by Rapp et al.94  Bowe et al. showed that Body Image Disturbance Questionnaire 
scores correlated with Skindex-16 scores92 . Significant correlation was found between Beck's 
depression inventory and APSEA188 .  
Gender differences  
In a population study of 1531 school pupils from Greece, the HRQoL of girls and boys 
were equally affected in those with acne 177.  Similarly, no difference was reported in other 
studies.27,110  In contrast, in several studies females were reported to experience a greater impact 
on QoL than males28,107,111,146, 187.   However in a study carried out in Egypt, the mean DLQI 
scores of male patients with acne were higher than those of female patients.55  
Racial and ethnic differences 
Gorelick et al.explored the impact of racial background on the perceived HRQoL impact of 
acne141, categorising subjects into “White”, “Black”, “Hispanic” and “Asian”. “White” and 
“Black” subjects reported less negative impact of acne on QoL than “Hispanic” and “Asian/other 
subjects” measured by the Acne-QoL. “Black” subjects reported significantly less negative 
impact in the self-perception domain compared with “Asian/other subjects”. By racial/ethnic 
group, social functioning was less negatively impacted by acne in “White” and “Black” subjects 
than in “Asian/other subjects”. There were no statistically significant differences in either the 
role-emotional or acne symptoms domains among racial/ethnic groups.141 Callender et al. did not 
find significant differences in HRQoL between white/Caucasian and non-white/Caucasian 
women with acne.140  
Comparison of generic and disease-specific QoL instruments  
Significant correlation in an acne population was reported between all domains of the SF-36 and 
the DLQI scores.34   The dermatology-specific instrument, the DLQI, was demonstrated to be 
more responsive to change compared to the two generic measures, the SF-36 and EQ-5D.61 
Comparison of QoL impairment in patients with acne and other diseases  
Patients with acne experienced functioning and emotional effects from their skin disease 
comparable with those experienced by patients with psoriasis, but had fewer symptoms.85  
Patients with severe acne reported levels of social, psychological and emotional problems that 
were as great as those reported by patients with chronic disabling asthma, epilepsy, diabetes, 
back pain or arthritis.60 In the study from Brazil, patients with acne had the fourth highest quimp, 
surpassed only by psoriasis, vitiligo and atopic dermatitis.29 In children psoriasis and atopic 
dermatitis caused the greatest impairment of QoL, followed by urticaria and acne.176 
Discussion 
In all studies reviewed, the measures used detected impairment of QoL caused by acne. Acne, 
especially when severe, may have an impact on the life of patients comparable to that caused by 
other dermatologic diseases, such as psoriasis, vitiligo, atopic dermatitis and urticaria,29, 85, 176 
and non-dermatologic diseases, such as asthma, epilepsy, diabetes, back pain and arthritis60. In 
the study by Sampogna et al 208 , the only skin diseases that had a greater psychosocial impact 
than acne were hyperhidrosis, hirsutism, ectoparasitic infections and bullous diseases. 
The DLQI, a dermatology-specific instrument, and the acne-specific instruments CADI and 
Acne-QoL were used much more frequently than the generic SF-36 questionnaire. The 
dermatology-specific instruments СDLQI and Skindex-29 were also both used more than 10 
times. This may reflect a higher interest amongst investigators in assessing dermatology- and 
acne-specific aspects of HRQoL impairment. Currently in routine clinical practice HRQoL 
assessment is still infrequent despite there being many potential benefits from such use.15 
 The dermatology-specific questionnaire the DLQI showed greater response sensitivity following 
successful treatment than the generic SF-36 and EQ-5D instruments.61 Appropriate response is 
especially important in clinical trials, the commonest reported context for QoL measurement in 
acne patients.  The instruments most used in clinical trials are the DLQI and CADI.  
The impairment of QoL in patients with acne has been reported in epidemiologic studies 
in various countries.31,62,103,110,111,177  The impact on QoL correlates with acne severity in some 
but not all studies, underlying the need for the effective and timely management of acne even for 
patients with less severe acne.62,103,177  
The major impact of acne on HRQoL documented in the reviewed studies emphasizes the need 
for educational programs for acne patients about living with and treating acne.39,51 At the 
moment an educational approach is much less developed than in atopic dermatitis or psoriasis.  
The creation and critical evaluation of high quality educational programs should be given 
priority by organizations that focus on acne, researchers and clinicians. QoL assessment may be 
used in this context as an outcome measure and source of additional information from patients.  
Prediction of compliance and adherence to treatment in acne patients is another potential aspect 
of the use of HRQoL instruments. However, current evidence suggests that this is not an easy 
task.25, 83, 142 Probably, when starting a new treatment, those patients with the most highly 
impaired HRQoL generally adhere better to the therapy.  From a longer-term perspective, those 
patients whose acne improved the most showed improvement in their HRQoL and had superior 
adherence to therapy.  
Impaired QoL is also often associated with significant psychological problems in acne 
patients.65,92,94,188  Gender differences may also play a role.  Although acne affects female and 
male adolescents in about the same proportion, a higher impact on QoL in females compared to 
males has been shown in several studies. 28,107,111,146,187  No gender difference was found in other 
studies27,110, 177  There is only one report 55 of male patients having a greater impact of acne on 
their QoL, probably influenced by local regional peculiarities. It may be that racial and ethnic 
differences in QoL assessment by acne patients141 are also based on difference in cultural 
attitudes.  
As different studies examine different age ranges of subjects and use different HRQoL 
questionnaires, there is little standardization of results, emphasising the need for the 
development of agreed core outcome measures for use across all studies. 
During this review, many examples were identified of inappropriate use or reporting of QoL 
measurement in acne.  These included use of “study-specific” unvalidated questionnaires that 
included elements of QoL, inaccurate presentation of titles of QoL instruments, absence of 
information on instruments and use of QoL instruments out of their validated age limits. Similar 
problems were also reported concerning QoL measurement in patients with atopic dermatitis.209 
Such activity reduces the scientific value of published results and may discredit HRQoL 
assessment. There is a need for educated input when researchers plan studies that include 
HRQoL assessment and a need for editors to set clear standards for the reporting of HRQoL data. 
On the basis of this literature review and expert opinion our Task Forces recommend the DLQI, 
CDLQI and Skindex-29 as dermatology-specific, CADI and Acne-QoL as acne-specific and SF-
36 as generic instruments for the assessment of HRQoL in acne. Experience of the use in acne of 
other instruments presented in this paper is too limited. The brevity of the DLQI, CDLQI and 
CADI and Acne-QoL makes these instruments suitable for use in routine clinical practice. Acne-
specific instruments may assess HRQoL in both children and young adults.210 It is acknowledged 
that some of the recommended measures may not have ideal validation characteristics. 
The recommendations of the Task Forces are given in Figures 3 and 4. 
 
Table 1. Details of HRQoL instruments that were used in articles reviewed 
 
Figure 1. Literature search procedure 
  
Figure 2. Number of studies in which each HRQoL instrument was used 
  
Figure 3. Task Forces recommendations for use of HRQoL measures in acne 
  
Figure 4.  Flow chart to assist selection of appropriate HRQoL instrument 
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